ArticleJournal of diabetes and its complications2026
Inflammatory profile associated with hyperglycemia in children with type 1 diabetes.
Article in Journal of diabetes and its complications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundComplications of type 1 diabetes (T1D) are associated with exposure to hyperglycemia. Inflammation is involved in microvascular and macrovascular complications, but associations between hyperglycemia and inflammatory mediators across multiple classes have not been comprehensively described. We aimed to characterize the inflammatory profile associated with hyperglycemia in children with T1D.
methodsWe comprehensively evaluated blood inflammatory mediators (cytokines, chemokines, growth factors, matrix metalloproteinases (MMPs)) using multiplex immunoassays in 117 children with T1D. We used multiple linear regression analyses to assess the relations between inflammatory mediators (transformed to robust z-scores) and hemoglobin A1c (HbA1c), adjusting for age, diabetes duration and body mass index. We computed an inflammatory composite as the within-person mean of significantly associated robust z-scores.
resultsLevels of multiple inflammatory mediators were associated with HbA1c (p < 0.05 and False Discovery Rate-adjusted q < 0.10). These included cytokines [interleukin (IL)-1β, IL-1 receptor antagonist, IL-2, IL-4, IL-6, IL-8, IL-13, IL-17A, IL-17F, IL-18, IL-20, IL-21, IL-23, IL-33, interferon-γ, tumor necrosis factor (TNF)-α, TNF-related apoptosis inducing ligand (TRAIL), thrombopoietin, stem cell factor, leukemia inhibitory factor, chemokines (CCL1, CCL2, CCL4, CCL7, CCL8, CCL13, CCL26, CCL27, CXCL1, CXCL5, CXCL13), growth factors (vascular endothelial growth factor-A, transforming growth factor-α, platelet derived growth factor-AA), and MMPs (MMP-1, MMP-2, tissue inhibitor of MMP-1). Each percentage point increase in HbA1c was associated with a 0.16 increase in inflammatory composite score.
conclusionsA broad range of inflammatory mediators are correlated with HbA1c in children with T1D. These inflammatory changes precede development of T1D complications, suggesting that possible pathophysiologic involvement should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.